Peripheral neutrophils from sAH patients initially express low levels of IL-8. However, upon infiltrating the sAH liver, these neutrophils are stimulated by the inflammatory environment, including mediators such as TNF-α and IL-1β, to produce high levels of IL-8. This IL-8 production amplifies systemic IL-8 levels, further recruiting neutrophils to the liver and perpetuating a vicious cycle of inflammation. As central drivers of this inflammatory loop, IL-8, Neutrophils represent promising therapeutic targets for managing sAH. Diagram was created with BioRender.com. AH, alcohol-associated hepatitis; IL, interleukin; sAH, severe AH; TNF, tumor necrosis factor. Credit: Yukun Guan, Dechun Feng, Luca Maccioni, Yang Wang, Bin Gao.
Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated risk of mortality in its severe form (sAH). While the condition has been studied extensively, effective treatments remain scarce, with liver transplantation often being the only viable option for patients with advanced disease.
In his recent editorial, Dr. Bin Gao and his colleagues at the National Institutes of Health provide an in-depth analysis of IL-8, Neutrophils, which are implicated as central drivers of the inflammation associated with sAH. The editorial consolidates findings from multiple studies, shedding light on the molecular mechanisms that underpin the condition and identifying IL-8 signaling as a potential therapeutic pathway.
Neutrophil infiltration, a hallmark of sAH, is driven by elevated levels of IL-8, a chemokine crucial in recruiting and activating immune cells. Unlike other liver diseases, sAH features an abundance of IL-8., neutrophils within the liver, amplifying a vicious cycle of inflammation and tissue damage. These unique characteristics make IL-8, Neutrophils an attractive focus for therapeutic interventions.
“By targeting IL-8, Neutrophils, we can develop treatments that selectively reduce inflammation in sAH without affecting other liver conditions,” said Dr. Gao.
The editorial highlights several strategies for targeting IL-8 signaling. These include therapeutic antibodies like ABX-IL-8 and HuMax-IL-8 (BMS-986253), CXCR1/CXCR2 inhibitors, and p38 MAPK inhibitors.
The authors emphasize the importance of addressing potential challenges, including the risk of infections when using anti-IL-8 therapies. They propose combination approaches, such as pairing anti-IL-8 agents with antibiotics or IL-22, a cytokine with hepatoprotective effects, to enhance safety and efficacy.
The editorial also underscores the broader relevance of IL-8, Neutrophils beyond sAH. These cells have been implicated in other inflammatory and neoplastic conditions, such as severe COVID-19 and hepatocellular carcinoma, indicating their potential as universal therapeutic targets.
While the editorial does not present new experimental data, it synthesizes existing findings to propose a clear direction for future research. By focusing on IL-8, Neutrophils, the authors aim to catalyze the development of targeted therapies that could transform the treatment landscape for sAH and related conditions.
“Our work highlights the critical role of IL-8+ neutrophils in sAH and underscores the need for interdisciplinary collaboration to develop effective therapies,” Dr. Gao said.
As the field of hepatology advances, integrating insights from molecular biology, immunology, and pharmacology will be essential. This editorial is a valuable roadmap for researchers and clinicians seeking to address the unmet medical needs associated with sAH, improving patient outcomes worldwide.
More information:
Yukun Guan et al, New therapeutic target for alcohol-associated hepatitis (AH): AH-associated IL-8+neutrophils, eGastroenterology (2024). DOI: 10.1136/egastro-2024-100166
Provided by First Hospital of Jilin University
Citation: Exploring IL-8⁺ neutrophils and their role in severe alcohol-associated hepatitis (2025, January 6) retrieved 6 January 2025 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
